{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:27:44Z","timestamp":1763141264837,"version":"3.37.3"},"reference-count":90,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Glioblastoma (GBM) is a challenging diagnosis with almost universally poor prognosis. Though the survival advantage of postoperative radiation (RT) is well established, around 90% of patients will fail in the RT field. The high likelihood of local failure suggests the efficacy of RT needs to be improved to improve clinical outcomes. Radiosensitizers are an established method of enhancing RT cell killing through the addition of a pharmaceutical agent. Though the majority of trials using radiosensitizers have historically been unsuccessful, there continues to be interest with a variety of approaches having been employed. Epidermal growth factor receptor inhibitors, histone deacetylase inhibitors, antiangiogenic agents, and a number of other molecularly targeted agents have all been investigated as potential methods of radiosensitization in the temozolomide era. Outcomes have varied both in terms of toxicity and survival, but some agents such as valproic acid and bortezomib have demonstrated promising results. However, reporting of results in phase 2 trials in newly diagnosed GBM have been inconsistent, with no standard in reporting progression-free survival and toxicity. There is a pressing need for investigation of new agents; however, nearly all phase 3 trials of GBM patients of the past 25 years have demonstrated no improvement in outcomes. One proposed explanation for this is the selection of agents lacking sufficient preclinical data and\/or based on poorly designed phase 2 trials. Radiosensitization may represent a viable strategy for improving GBM outcomes in newly diagnosed patients, and further investigation using agents with promising phase 2 data is warranted.<\/jats:p>","DOI":"10.1093\/nop\/npz057","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T16:19:51Z","timestamp":1575303591000},"page":"268-276","source":"Crossref","is-referenced-by-count":10,"title":["Radiosensitizers in the temozolomide era for newly diagnosed glioblastoma"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1077-120X","authenticated-orcid":false,"given":"Peter","family":"Mathen","sequence":"first","affiliation":[{"name":"Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay","family":"Rowe","sequence":"first","affiliation":[{"name":"Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Mackey","sequence":"first","affiliation":[{"name":"Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DeeDee","family":"Smart","sequence":"first","affiliation":[{"name":"Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Tofilon","sequence":"first","affiliation":[{"name":"Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Camphausen","sequence":"first","affiliation":[{"name":"Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,11,30]]},"reference":[{"key":"2020060510400999500_CIT0001","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/neuonc\/not151","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010","volume":"15","author":"Ostrom","year":"2013","journal-title":"Neuro Oncol"},{"year":"2018","author":"National Comprehensive Cancer Network","key":"2020060510400999500_CIT0002"},{"issue":"4","key":"2020060510400999500_CIT0003","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.semradonc.2016.06.003","article-title":"Success and failures of combined modalities in glioblastoma multiforme: old problems and new directions","volume":"26","author":"Corso","year":"2016","journal-title":"Semin Radiat Oncol."},{"issue":"10","key":"2020060510400999500_CIT0004","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med."},{"issue":"1 pt 1","key":"2020060510400999500_CIT0005","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1148\/radiology.170.1.2535765","article-title":"Human cerebral gliomas: correlation of postmortem MR imaging and neuropathologic findings","volume":"170","author":"Johnson","year":"1989","journal-title":"Radiology."},{"issue":"3","key":"2020060510400999500_CIT0006","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3171\/jns.1978.49.3.0333","article-title":"Evaluation of BCNU and\/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial","volume":"49","author":"Walker","year":"1978","journal-title":"J Neurosurg."},{"issue":"4","key":"2020060510400999500_CIT0007","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/bjc.1991.396","article-title":"A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party","volume":"64","author":"Bleehen","year":"1991","journal-title":"Br J Cancer."},{"issue":"3","key":"2020060510400999500_CIT0008","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0167-8140(02)00078-6","article-title":"Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review","volume":"64","author":"Laperriere","year":"2002","journal-title":"Radiother Oncol."},{"issue":"2","key":"2020060510400999500_CIT0009","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s11060-010-0251-4","article-title":"Radiographic patterns of relapse in glioblastoma","volume":"101","author":"Chamberlain","year":"2011","journal-title":"J Neurooncol."},{"issue":"1","key":"2020060510400999500_CIT0010","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1038\/s41598-018-22697-9","article-title":"Retrospective analysis of radiological recurrence patterns in glioblastoma, their prognostic value and association to postoperative infarct volume","volume":"8","author":"Bette","year":"2018","journal-title":"Sci Rep."},{"issue":"7","key":"2020060510400999500_CIT0011","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00066-004-1220-7","article-title":"Radiotherapy for high-grade gliomas. Does altered fractionation improve the outcome?","volume":"180","author":"Nieder","year":"2004","journal-title":"Strahlenther Onkol."},{"issue":"6","key":"2020060510400999500_CIT0012","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.2002.20.6.1635","article-title":"Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy","volume":"20","author":"Chan","year":"2002","journal-title":"J Clin Oncol."},{"issue":"3","key":"2020060510400999500_CIT0013","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ijrobp.2004.04.011","article-title":"Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol","volume":"60","author":"Souhami","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"2","key":"2020060510400999500_CIT0014","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/neuonc\/5.2.79","article-title":"A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma","volume":"5","author":"Westphal","year":"2003","journal-title":"Neuro Oncol."},{"issue":"2","key":"2020060510400999500_CIT0015","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1227\/00006123-200208000-00009","article-title":"The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine","volume":"51","author":"Selker","year":"2002","journal-title":"Neurosurgery."},{"issue":"5","key":"2020060510400999500_CIT0016","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1200\/JCO.2002.20.5.1375","article-title":"Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide","volume":"20","author":"Stupp","year":"2002","journal-title":"J Clin Oncol."},{"issue":"34","key":"2020060510400999500_CIT0017","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1200\/JCO.2008.18.0612","article-title":"Phase I\/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177","volume":"26","author":"Brown","year":"2008","journal-title":"J Clin Oncol."},{"issue":"4","key":"2020060510400999500_CIT0018","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2008.18.9639","article-title":"Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma","volume":"27","author":"Prados","year":"2009","journal-title":"J Clin Oncol."},{"issue":"1","key":"2020060510400999500_CIT0019","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11060-009-0067-2","article-title":"Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme","volume":"98","author":"Peereboom","year":"2010","journal-title":"J Neurooncol."},{"issue":"9","key":"2020060510400999500_CIT0020","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/neuonc\/nou328","article-title":"A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K","volume":"17","author":"Ma","year":"2015","journal-title":"Neuro Oncol."},{"issue":"5","key":"2020060510400999500_CIT0021","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/neuonc\/nox209","article-title":"A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913","volume":"20","author":"Chinnaiyan","year":"2018","journal-title":"Neuro Oncol."},{"issue":"5","key":"2020060510400999500_CIT0022","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.ijrobp.2015.04.038","article-title":"A phase 2 study of concurrent radiation therapy, temozolomide, and the histone deacetylase inhibitor valproic acid for patients with glioblastoma","volume":"92","author":"Krauze","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"4","key":"2020060510400999500_CIT0023","first-page":"246","article-title":"Late toxicity in long-term survivors from a phase 2 study of concurrent radiation therapy, temozolomide and valproic acid for newly diagnosed glioblastoma","volume":"5","author":"Krauze","year":"2018","journal-title":"Neurooncol Pract."},{"issue":"4","key":"2020060510400999500_CIT0024","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/neuonc\/nox161","article-title":"Phase I\/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874\/ABTC 02","volume":"20","author":"Galanis","year":"2018","journal-title":"Neuro Oncol."},{"issue":"12","key":"2020060510400999500_CIT0025","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/neuonc\/nor130","article-title":"Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma","volume":"13","author":"Butowski","year":"2011","journal-title":"Neuro Oncol."},{"issue":"16","key":"2020060510400999500_CIT0026","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1158\/1078-0432.CCR-14-3220","article-title":"A multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma patients","volume":"21","author":"Lee","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"5","key":"2020060510400999500_CIT0027","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.ijrobp.2004.08.023","article-title":"A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma","volume":"61","author":"Butowski","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"25","key":"2020060510400999500_CIT0028","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.1200\/JCO.2008.21.6895","article-title":"Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial","volume":"27","author":"Grossman","year":"2009","journal-title":"J Clin Oncol."},{"issue":"5","key":"2020060510400999500_CIT0029","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.ijrobp.2018.01.001","article-title":"Phase 2 study of bortezomib combined with temozolomide and regional radiation therapy for upfront treatment of patients with newly diagnosed glioblastoma multiforme: safety and efficacy assessment","volume":"100","author":"Kong","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"5998","key":"2020060510400999500_CIT0030","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/313144a0","article-title":"Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin","volume":"313","author":"Libermann","year":"1985","journal-title":"Nature."},{"issue":"15","key":"2020060510400999500_CIT0031","first-page":"4307","article-title":"The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner","volume":"62","author":"Chakravarti","year":"2002","journal-title":"Cancer Res."},{"issue":"2","key":"2020060510400999500_CIT0032","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0360-3016(01)01609-1","article-title":"EGFR overexpression and radiation response in glioblastoma multiforme","volume":"51","author":"Barker","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"1","key":"2020060510400999500_CIT0033","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1215\/S1522851705000451","article-title":"Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma","volume":"8","author":"Prados","year":"2006","journal-title":"Neuro Oncol."},{"issue":"2","key":"2020060510400999500_CIT0034","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/neuonc\/nou164","article-title":"The mTOR signaling pathway as a treatment target for intracranial neoplasms","volume":"17","author":"Pachow","year":"2015","journal-title":"Neuro Oncol."},{"issue":"6","key":"2020060510400999500_CIT0035","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1158\/2159-8290.CD-11-0124","article-title":"Oncogenic EGFR signaling activates an mTORC2-NF-\u03baB pathway that promotes chemotherapy resistance","volume":"1","author":"Tanaka","year":"2011","journal-title":"Cancer Discov."},{"issue":"6167","key":"2020060510400999500_CIT0036","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.1239947","article-title":"Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma","volume":"343","author":"Johnson","year":"2014","journal-title":"Science."},{"issue":"24","key":"2020060510400999500_CIT0037","first-page":"7291","article-title":"Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy","volume":"62","author":"Eshleman","year":"2002","journal-title":"Cancer Res."},{"issue":"10","key":"2020060510400999500_CIT0038","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1593\/neo.05361","article-title":"Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells","volume":"7","author":"Rao","year":"2005","journal-title":"Neoplasia."},{"issue":"3","key":"2020060510400999500_CIT0039","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O\u2019Reilly","year":"2006","journal-title":"Cancer Res."},{"issue":"1","key":"2020060510400999500_CIT0040","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/neuonc\/not139","article-title":"The mTORC1\/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells","volume":"16","author":"Kahn","year":"2014","journal-title":"Neuro Oncol."},{"issue":"3","key":"2020060510400999500_CIT0041","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/ijc.20774","article-title":"Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid","volume":"114","author":"Camphausen","year":"2005","journal-title":"Int J Cancer."},{"issue":"17","key":"2020060510400999500_CIT0042","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1158\/1078-0432.CCR-08-0643","article-title":"Postradiation sensitization of the histone deacetylase inhibitor valproic acid","volume":"14","author":"Chinnaiyan","year":"2008","journal-title":"Clin Cancer Res."},{"issue":"12","key":"2020060510400999500_CIT0043","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1212\/WNL.0b013e31822f02e1","article-title":"Prolonged survival with valproic acid use in the EORTC\/NCIC temozolomide trial for glioblastoma","volume":"77","author":"Weller","year":"2011","journal-title":"Neurology."},{"issue":"3","key":"2020060510400999500_CIT0044","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ijrobp.2013.02.012","article-title":"Valproic acid use during radiation therapy for glioblastoma associated with improved survival","volume":"86","author":"Barker","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"7","key":"2020060510400999500_CIT0045","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/neuonc\/not057","article-title":"Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme","volume":"15","author":"Kerkhof","year":"2013","journal-title":"Neuro Oncol."},{"issue":"7","key":"2020060510400999500_CIT0046","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1200\/JCO.2015.63.6563","article-title":"Does valproic acid or levetiracetam improve survival in glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed glioblastoma","volume":"34","author":"Happold","year":"2016","journal-title":"J Clin Oncol."},{"issue":"25","key":"2020060510400999500_CIT0047","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1200\/JCO.2016.67.2162","article-title":"Valproate in adjuvant glioblastoma treatment","volume":"34","author":"Fay","year":"2016","journal-title":"J Clin Oncol."},{"issue":"1","key":"2020060510400999500_CIT0048","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijrobp.2004.12.088","article-title":"Modulation of radiation response by histone deacetylase inhibition","volume":"62","author":"Chinnaiyan","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"21","key":"2020060510400999500_CIT0049","first-page":"7291","article-title":"Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA","volume":"63","author":"Kim","year":"2003","journal-title":"Cancer Res."},{"issue":"8","key":"2020060510400999500_CIT0050","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrn2175","article-title":"Angiogenesis in brain tumours","volume":"8","author":"Jain","year":"2007","journal-title":"Nat Rev Neurosci."},{"issue":"8","key":"2020060510400999500_CIT0051","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N Engl J Med."},{"issue":"8","key":"2020060510400999500_CIT0052","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med."},{"issue":"7","key":"2020060510400999500_CIT0053","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/00000478-199807000-00004","article-title":"Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma","volume":"22","author":"Chan","year":"1998","journal-title":"Am J Surg Pathol."},{"issue":"9","key":"2020060510400999500_CIT0054","first-page":"3369","article-title":"The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival","volume":"9","author":"Zhou","year":"2003","journal-title":"Clin Cancer Res."},{"issue":"3","key":"2020060510400999500_CIT0055","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1023\/A:1016297611825","article-title":"Antiangiogenic and antitumor effects of a protein kinase C\u03b2 inhibitor in human breast cancer and ovarian cancer xenografts","volume":"20","author":"Teicher","year":"2002","journal-title":"Invest New Drugs."},{"issue":"2","key":"2020060510400999500_CIT0056","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/ana.21057","article-title":"Synergistic antiglioma activity of radiotherapy and enzastaurin","volume":"61","author":"Tabatabai","year":"2007","journal-title":"Ann Neurol."},{"issue":"16","key":"2020060510400999500_CIT0057","first-page":"4645","article-title":"ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration","volume":"62","author":"Wedge","year":"2002","journal-title":"Cancer Res."},{"issue":"24","key":"2020060510400999500_CIT0058","first-page":"7284","article-title":"ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases","volume":"62","author":"Carlomagno","year":"2002","journal-title":"Cancer Res."},{"issue":"22","key":"2020060510400999500_CIT0059","doi-asserted-by":"crossref","first-page":"8145","DOI":"10.1158\/1078-0432.CCR-05-0319","article-title":"ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors","volume":"11","author":"Rich","year":"2005","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2020060510400999500_CIT0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-008-9527-3","article-title":"Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model","volume":"88","author":"Sandstr\u00f6m","year":"2008","journal-title":"J Neurooncol."},{"issue":"6","key":"2020060510400999500_CIT0061","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/sj.bjc.6602108","article-title":"The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model","volume":"91","author":"Sandstr\u00f6m","year":"2004","journal-title":"Br J Cancer."},{"issue":"15","key":"2020060510400999500_CIT0062","doi-asserted-by":"crossref","first-page":"5639","DOI":"10.1158\/1078-0432.CCR-05-0174","article-title":"Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma","volume":"11","author":"Damiano","year":"2005","journal-title":"Clin Cancer Res."},{"issue":"4","key":"2020060510400999500_CIT0063","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S0959-8049(00)00430-5","article-title":"Effects of a novel synthetic retinoid on malignant glioma in vitro: inhibition of cell proliferation, induction of apoptosis and differentiation","volume":"37","author":"Costa","year":"2001","journal-title":"Eur J Cancer."},{"issue":"2","key":"2020060510400999500_CIT0064","first-page":"417","article-title":"Combination interferon-alpha2a and 13-cis-retinoic acid enhances radiosensitization of human malignant glioma cells in vitro","volume":"5","author":"Malone","year":"1999","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2020060510400999500_CIT0065","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1023\/A:1006426917654","article-title":"Extracellular glutamate and other metabolites in and around RG2 rat glioma: an intracerebral microdialysis study","volume":"47","author":"Behrens","year":"2000","journal-title":"J Neurooncol."},{"issue":"9","key":"2020060510400999500_CIT0066","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/nm0901-1010","article-title":"Glutamate release promotes growth of malignant gliomas","volume":"7","author":"Takano","year":"2001","journal-title":"Nat Med."},{"issue":"1","key":"2020060510400999500_CIT0067","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.nurt.2006.11.001","article-title":"Talampanel","volume":"4","author":"Howes","year":"2007","journal-title":"Neurotherapeutics."},{"issue":"17","key":"2020060510400999500_CIT0068","first-page":"4383","article-title":"Glioma cells release excitotoxic concentrations of glutamate","volume":"59","author":"Ye","year":"1999","journal-title":"Cancer Res."},{"issue":"9","key":"2020060510400999500_CIT0069","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nm746","article-title":"Blockage of Ca(2+)-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells","volume":"8","author":"Ishiuchi","year":"2002","journal-title":"Nat Med."},{"issue":"7","key":"2020060510400999500_CIT0070","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/cncr.24957","article-title":"Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas","volume":"116","author":"Iwamoto","year":"2010","journal-title":"Cancer."},{"issue":"6","key":"2020060510400999500_CIT0071","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2174\/1568009614666140804154511","article-title":"Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system","volume":"14","author":"Dou","year":"2014","journal-title":"Curr Cancer Drug Targets."},{"issue":"5","key":"2020060510400999500_CIT0072","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","article-title":"The proteasome: a suitable antineoplastic target","volume":"4","author":"Adams","year":"2004","journal-title":"Nat Rev Cancer."},{"issue":"3","key":"2020060510400999500_CIT0073","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/156800911794519752","article-title":"Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives","volume":"11","author":"Chen","year":"2011","journal-title":"Curr Cancer Drug Targets."},{"issue":"7","key":"2020060510400999500_CIT0074","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1056\/NEJMoa1006312","article-title":"NFKBIA deletion in glioblastomas","volume":"364","author":"Bredel","year":"2011","journal-title":"N Engl J Med."},{"issue":"6B","key":"2020060510400999500_CIT0075","first-page":"4499","article-title":"Activity of bortezomib in glioblastoma","volume":"26","author":"Styczynski","year":"2006","journal-title":"Anticancer Res."},{"issue":"3","key":"2020060510400999500_CIT0076","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/sj.onc.1208225","article-title":"Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM)","volume":"24","author":"Yin","year":"2005","journal-title":"Oncogene."},{"issue":"1-2","key":"2020060510400999500_CIT0077","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11010-013-1835-z","article-title":"Inhibition of autophagy enhances apoptosis induced by proteasome inhibitor bortezomib in human glioblastoma U87 and U251 cells","volume":"385","author":"Zhang","year":"2014","journal-title":"Mol Cell Biochem."},{"issue":"2","key":"2020060510400999500_CIT0078","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ijrobp.2008.08.050","article-title":"Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies","volume":"74","author":"Kubicek","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"1","key":"2020060510400999500_CIT0079","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/neuonc\/nox144","article-title":"Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma","volume":"20","author":"Mandel","year":"2018","journal-title":"Neuro Oncol."},{"issue":"10","key":"2020060510400999500_CIT0080","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1080\/14737140.2018.1496824","article-title":"Highlighting the need for reliable clinical trials in glioblastoma","volume":"18","author":"Mandel","year":"2018","journal-title":"Expert Rev Anticancer Ther."},{"key":"2020060510400999500_CIT0081","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1200\/jco.2013.31.15_suppl.2065","article-title":"Phase I Adult Brain Tumor Consortium (ABTC) trial of ABT-888 (veliparib), temozolomide (TMZ), and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM) including pharmacokinetic (PK) data","volume":"31","author":"Kleinberg","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020060510400999500_CIT0082","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol."},{"issue":"10","key":"2020060510400999500_CIT0083","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1093\/neuonc\/not100","article-title":"Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation","volume":"15","author":"Wick","year":"2013","journal-title":"Neuro Oncol."},{"key":"2020060510400999500_CIT0084","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1200\/JCO.2019.37.15_suppl.2042","article-title":"Health-related quality of life (HRQL) in VERTU: A randomized phase II trial of veliparib (V), radiotherapy (RT), and temozolomide (TMZ) for newly diagnosed MGMT unmethylated (uMGMT) glioblastoma (GBM)","volume":"37","author":"Sim","year":"2019","journal-title":"J Clin Oncol"},{"key":"2020060510400999500_CIT0085","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/jco.2015.33.15_suppl.2013","article-title":"Randomized, placebo-controlled, phase II study of dasatinib with standard chemo-radiotherapy for newly diagnosed glioblastoma (GBM), NCCTG N0877 (Alliance)","volume":"33","author":"Laack","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020060510400999500_CIT0086","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/neuonc\/noq008","article-title":"Prolonged survival for patients with newly diagnosed, inoperable glioblastoma with 3-times daily ultrafractionated radiation therapy","volume":"12","author":"Beauchesne","year":"2010","journal-title":"Neuro Oncol."},{"key":"2020060510400999500_CIT0087","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1200\/jco.2011.29.15_suppl.2073","article-title":"Concurrent, 3-times daily ultrafractionated radiation therapy and temozolomide for newly inoperable glioblastoma: TEMOFRAC a phase II trial","volume":"29","author":"Beauchesnes","year":"2011","journal-title":"J Clin Oncol"},{"issue":"28","key":"2020060510400999500_CIT0088","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J Clin Oncol."},{"issue":"5","key":"2020060510400999500_CIT0089","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","article-title":"Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma","volume":"27","author":"Kreisl","year":"2009","journal-title":"J Clin Oncol."},{"issue":"2","key":"2020060510400999500_CIT0090","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1200\/JCO.2010.30.2729","article-title":"Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme","volume":"29","author":"Lai","year":"2011","journal-title":"J Clin Oncol."}],"container-title":["Neuro-Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/nop\/article-pdf\/7\/3\/268\/33347708\/npz057.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/nop\/article-pdf\/7\/3\/268\/33347708\/npz057.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T08:22:22Z","timestamp":1591431742000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nop\/article\/7\/3\/268\/5648944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,30]]},"references-count":90,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,11,30]]},"published-print":{"date-parts":[[2020,6,5]]}},"URL":"https:\/\/doi.org\/10.1093\/nop\/npz057","relation":{},"ISSN":["2054-2577","2054-2585"],"issn-type":[{"type":"print","value":"2054-2577"},{"type":"electronic","value":"2054-2585"}],"subject":[],"published-other":{"date-parts":[[2020,6]]},"published":{"date-parts":[[2019,11,30]]}}}